Latest news with #ViralShah
Time of India
a day ago
- Entertainment
- Time of India
Manasi Parekh: After the National Award, people have suddenly started taking me seriously
Manasi Parekh Manasi Parekh has always chosen the road less travelled. While many in her place might have waited for mainstream validation, she focused on carving her own path, particularly within the Gujarati industry. After producing and starring in Kutch Express, directed by Viral Shah, which earned her the Best Actress National Award last year, things began to shift for her professionally. She will soon be seen in Maharani, backed by Kumar Mangat Pathak and Abhishek Pathak, marking her second collaboration with Viral. The film explores the dynamic between a house help and her employer. Manasi with Shraddha Dangar in a still from Maharani Reflecting on her journey, in a chat with Mumbai Mirror, she shares, 'After Uri , I honestly didn't get as many interesting roles in Hindi as I had hoped. But I'm very enterprising, so instead of complaining, I decided to create opportunities for myself. When you're following your inner voice and not walking a path already taken, people tend to misjudge you. Bahot logon ko lagta hai, Gujarati mein kya kar legi?' That realisation prompted her to return to her roots. She says, 'I'm Gujarati, and I love my language. I thought, why not start something here? I began taking small steps. Kutch Express was our second production, and it went on to win three National Awards. That's when people started taking me seriously. They realised I wasn't just talking; I was letting my work speak.' The recognition, she says, has brought both respect and renewed faith in her artistic choices. She says, 'I worked hard for this. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Your New Zealand escape starts with Singapore Airlines Fly with Singapore Airlines Book Now Undo I made sure to back scripts that gave women a voice. As a producer, I was clear about that. And as an actor, I've always tried to create space for myself without imitating anyone else. That's what led to the National Award. Post that, there's a greater sense of respect and trust in my work. People have begun to see that I'm here for the long haul. ' Now that expectations have grown, does it feel like an added responsibility? She replies, 'Absolutely, but it's not a burden. I don't let it become this image I have to maintain. I don't suddenly start taking myself too seriously just because I've won a National Award. That mindset can be a trap. I've seen so many people get caught up in the image game, thinking this is my brand, this is how I should project myself. But that's not sustainable. Aaj hai, kal nahi hoga. Over my 20-year journey, I've seen people come and go. Some achieve great things and then disappear. So, the only thing you can do is stay humble, work hard, show up on time, and be professional. If you stick to these fundamental values, everything else will follow.'
Time of India
10-07-2025
- Entertainment
- Time of India
'Maharani' trailer: Manasi Parekh starrer explores household problems, bond between modern woman, housemaid
The trailer of Manasi Parekh, Shraddha Dangar, Ojas Rawal and Sanjay Goradia starrer 'is out now. The trailer of Manasi Parekh , Shraddha Dangar, Ojas Rawal and Sanjay Goradia starrer 'Maharani' is out now. The trailer shows modern-day household problems and the search for a perfect maid to manage household chores. It is a blend of humour and drama, and the story seems relatable. While talking about the film, actress Manasi Parekh said in a statement, "Working on this film made me realise that the bond we share with our housemaid is actually irreplaceable. 'Maharani' also reflects on women friendships, the idea of self-esteem, self love in the larger scheme of things. It is a story that goes beyond the usual, and collaborating with such great actors and a director like Viral feels surreal." She opened up about her character, saying, "My character, Manasi is just like any other independent working woman who has new situations that life throws everyday and she tries to cope with it in the best possible way." Shraddha added, "'Maharani' is an exceptionally written story, it connects with me personally at multiple levels. Rani's character showcases strength, self awareness and has many layers to it. The film is a comedy at its core, and I thoroughly enjoyed being a part of it." by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Padova: AudioNova cerca per un test 700 persone nate prima del 1974 AudioNova Undo On talking about the entire idea behind the film, the director Viral Shah , shared, "'Maharani' is a celebration of unsung relationships - the kind that quietly unfold in kitchens, living rooms, and in the silent understanding shared over a cup of chai. At its core, it's a light-hearted, slice-of-life comedy, but it speaks volumes about the unspoken bond between a house owner and her house help. It's a story that gently reminds us that the freedom and ease we often take for granted are possible only because someone else is holding the fort behind the scenes. It's subtle, it's heartfelt, and it's a story that needed to be told." "'Maharani' is emotional, it's entertaining, and most of all, it's real. With a brilliant cast and a story that reflects every household, we're excited to bring this heartfelt comedy to audiences across the country," said Abhishek Pathak, Producer & MD, Panorama Studios. Directed by National award winner, Viral Shah, presented by Panorama Studios 'Maharani' is a Monkey God Entertainment, Summit Studios and Eka Entertainment Production. Maharhas been produced by Kumar Mangat Pathak, Abhishek Pathak, Pritesh Thakkar, Madhu Sharma and Viral Shah. Alongside, co-produced by Murlidhar Chhatwani, Chandresh Bhanushali, Suchin Ahluwalia and Masumeh Makhija . 'Maharani' is set to release in the theatres on August 1.
Time of India
05-07-2025
- Business
- Time of India
Average home prices in state increased by 34% since FY18: GujRERA
Ahmedabad: Gujarat's real estate sector has witnessed a sharp rise in prices of residential units—up by 34% since 2017–18, driven by post-Covid demand and escalating input costs, according to a new report released by the Gujarat Real Estate Regulatory Authority (GujRERA). The report, 'Gujarat Real Estate Landscape: A Comprehensive Analysis of RERA Implementation and Infrastructure Growth', reveals that the average price of homes rose from Rs 40,231 per sq m in 2017–18 to Rs 54,139 per sq m in 2024–25, peaking at Rs 54,187 in 2023–24. The residential category assessed in the report includes a range of housing types such as apartments, bungalows, and row houses. You Can Also Check: Ahmedabad AQI | Weather in Ahmedabad | Bank Holidays in Ahmedabad | Public Holidays in Ahmedabad Industry experts attribute the surge to a steep rise in land acquisition and construction costs over the past few years. Viral Shah, vice president of CREDAI Ahmedabad, said, "Land prices have increased sharply, and construction costs have also risen drastically over the past few years. This has led to an overall spike in residential prices, although developers have not been able to pass on the full burden to buyers, thereby compressing profit margins. " Residential construction costs alone jumped from Rs 26,677 per sq m in 2017–18 to Rs 40,691 in 2024–25, reaching a high of Rs 41,895 per sq m in 2023–24. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 5 Books Warren Buffett Wants You to Read In 2025 Blinkist: Warren Buffett's Reading List Undo The report also notes that major districts in the state have not only seen a sustained price increase but also faced greater year-to-year fluctuations. In Ahmedabad, the average unit residential cost tells a more volatile story. From Rs 43 lakh in 2017–18, the price dipped to Rs 31 lakh in 2021–22 before surging to Rs 79 lakh in 2023–24. The rate moderated slightly to Rs 56 lakh in 2024–25. "This price trajectory reflects a maturing market responding to macroeconomic shifts, with developers balancing affordability and rising demand," the report noted. "The year-on-year average construction cost per square meter (carpet area) in Ahmedabad across all segments from FY 2017–18 to FY 2024–25 reflects a general upward trend, influenced by rising material costs, labour charges, and market demand. In the residential and group housing sector, costs increased from Rs 30,659 per sq m in 2017–18 to Rs 43,443 in 2024–25, with a notable peak at Rs 47,341 in 2023–24, indicating a steady rise driven by urbanisation pressures," the report stated. GFX sent to designers Table: Residential property prices District 2017-18 2020-21 2022-23 2023-24 2024-25 Ahmedabad 46,257 51,120 57,581 63,571 63,488 Vadodara 39,038 45,099 53,375 60,731 62,028 Surat 38,205 40,629 53,641 55,782 53,361 Rajkot 29,940 30,070 32,899 37,597 35,776 Gandhinagar 34,433 37,738 74,339 52,832 52,688 Other Dist 26,714 28,531 34,355 33,107 36,496 Source: GujRERA, prices in Rs/sq m)
Cision Canada
26-06-2025
- Business
- Cision Canada
JuliaHub Launches Dyad: Empowering Hardware Development at the Speed of Software
CAMBRIDGE, Mass., June 26, 2025 /CNW/ -- JuliaHub today unveiled Dyad, a powerful system that brings modern software agility to the world of hardware system design. A central theme behind our Dyad suite of tools is bringing together traditional physics-based modeling with Scientific Machine Learning (SciML) and Generative AI for model-based design in a way that's safe, interpretable, and engineer-approved for safety-critical applications. Dr. Viral Shah, JuliaHub CEO and Co-Creator of Julia, explains "Dyad leverages our significant experience with the Julia ecosystem that is trusted by over a million users worldwide. Working closely with customers across aerospace, semiconductors, manufacturing and energy industries, we have developed Dyad to overcome the challenges of yesterday's siloed tools." From fast prototyping to production deployment, Dyad supports the entire product lifecycle through: A textual programming interface that is first class for software development, and a Graphical User Interface (GUI) for engineers, with one-to-one mapping between the two interfaces Agentic AI workflows to develop models, convert models from legacy systems, and significantly improve engineer productivity through a focus on product design Integrated simulation and plotting workflows leveraging the rich ecosystem of analysis capabilities such as optimization and control systems already available via the Julia ecosystem Software engineering principles that help create scalable, collaborative projects centered around modeling, analysis and digital engineering SciML-native primitives that allow for model discovery, auto-completion of missing physics, and a seamless integration of field data into models for digital twins Importing and exporting of Functional Mock-up Units (FMUs) to interoperate with the rich ecosystem of upstream and downstream digital engineering tools Dr. Michael Tiller, designer of Dyad at JuliaHub adds: "Throughout my career, I've lamented the fact that engineering tools seem to be decades behind the state-of-the-art in software and technology. Dyad is our attempt to reimagine modeling, simulation and analysis tools to leverage fully modern technologies and capitalize on the incredible advances in AI." Dyad Studio is available under a source available license that allows engineers to see how Dyad works under the hood, and is free for educational and personal non-commercial use, with commercial licenses available from JuliaHub. More information is available at and About JuliaHub JuliaHub's mission is to empower those tackling the world's toughest scientific and technical challenges with cutting-edge tools in a seamless, secure environment. JuliaHub combines advanced mathematical computing and machine learning expertise to enable Scientific Machine Learning (SciML) techniques, Digital Twin modeling, and next-generation modeling and simulation in pharmaceutical, aerospace, automotive and other industries. Dyad brings together cloud-native infrastructure, differentiable programming, and modular extensibility to support next-generation engineering workflows. Dyad enables the development of continuously improving digital models by integrating AI with Scientific Machine Learning (SciML) in a safe, engineer-in-the-loop, environment. Dyad empowers teams to deploy smarter, faster, and more reliable systems without compromising the rigor of traditional engineering for over-the-air updates, predictive maintenance and real-time performance tuning. Dyad Studio is a powerful Visual Studio Code (VS Code) extension for the Dyad Modeling Language – engineered for professionals who need more than what traditional modeling GUIs can offer. Our next release will be Dyad Builder which provides a graphical user interface for quickly constructing and analyzing system level models. Both of these tools are part of our Dyad platform, an AI-enabled system modeling system built from the ground up for the era of Software-Defined Machines.
Medscape
26-06-2025
- Health
- Medscape
Semaglutide Benefits Adults With Type 1 Diabetes + Obesity
CHICAGO — Once-weekly semaglutide improved glycemia and reduced weight without increasing hypoglycemia in adults with type 1 diabetes (T1D) and obesity, new research presented at the American Diabetes Association (ADA) 85th Scientific Sessions found. The study results were simultaneously published in NEJM Evidence . 'Semaglutide was effective in lowering or improving time in range, without increasing time below range; it produced weight loss of at least 5%; and it was very safe,' said lead investigator Viral N. Shah, MD, professor of medicine and director of diabetes clinical research at the Center for Diabetes and Metabolic Diseases, Indiana University, Indianapolis. 'We didn't find any difference in severe hypoglycemia between semaglutide and a placebo, and we did not find any [diabetic ketoacidosis] in the entire study,' Shah told Medscape Medical News . 'I think the results are very encouraging, and I hope that industry will take it on and do a regulatory approval trial for semaglutide in type 1,' he added. Over a Third Met Composite Endpoint The 26-week ADJUST-T1D randomized clinical trial investigated semaglutide vs placebo in 72 adults with T1D and obesity (BMI ≥ 30) who were using automated insulin delivery (AID) systems. The trial was investigator-initiated and funded by Breakthrough T1D, not Ozempic manufacturer Novo Nordisk, although the company did provide the drug. A total of 72 patients were randomized 1:1 to receive once-weekly semaglutide, up to 1 mg, or placebo for 26 weeks. Participants had a mean age of 40 years, a mean diabetes duration of 23 years, a mean baseline A1c of 7.8, BMI 35, and body weight 102 kg. Two thirds were using the Tandem Control IQ AID system. The primary endpoint was a composite of continuous glucose monitoring (CGM)-based time in range 70-180 mg/dL of > 70%; time below 70 mg/dL of < 4%; and ≥ 5% weight reduction. A total of 13 of the 36 (36.1%) in the semaglutide group vs zero in the placebo group met the composite endpoint. The between-group difference was 36 percentage points ( P < .001). Semaglutide treatment was associated with a nearly eightfold better chance of achieving the primary outcome (odds ratio, 7.77). Among the secondary outcomes, A1c reductions from baseline to week 26 were 0.7 with semaglutide vs 0.4 with placebo; increased percent time in range was 11.1% vs 2.3%; reductions in CGM mean glucose were 15.7 mg/dL vs 3.6 mg/dL; and reductions in percentage time above 180 mg/dL were 11.1% vs 2.7%. All of those differences were significant, Shah reported. The percentage of time spent below 70 mg/dL from baseline was low and the change from baseline didn't differ significantly between the two groups, 0.1% vs 0.4%. Body weight change at 26 weeks were reductions of 9.2 kg vs 0.4 kg, and BMI drops were 3.3 vs 0.2. Those differences were also significant, Shah said. Daily insulin requirements from baseline to week 26 were reduced significantly by 22.3 units per day with the semaglutide group compared to the placebo group. A total of 57 gastrointestinal events were reported by 19 patients in the semaglutide group vs 13 gastrointestinal events were reported by 9 patients in the placebo group. Two from each group experienced severe hypoglycemia. There were no diabetic ketoacidosis events in either group. The number of people who discontinued the trial early due to persistent gastrointestinal adverse events was three in the placebo group vs two in the semaglutide group. 'Prohibitively Expensive for Those With T1D' Asked to comment, Nicholas B. Argento, MD, senior clinical endocrinologist and diabetes technology director at the Maryland Endocrine and Diabetes Center, Columbia, Maryland, said that the trial 'was small but showed the benefit of using adjunctive therapy in T1D.' There is an 'unmet need' in patients with T1D with a high BMI and suboptimal glycemic control, he told Medscape Medical News Despite proven cardiorenal benefits of both GLP-1 agonists and SGLT2 inhibitors in type 2 diabetes, 'none are approved for use in T1D, which means that they are generally not covered by insurance.' These medications 'end up being prohibitively expensive for those withT1D to access,' Argento noted. But there is no reason to believe we would not see similar benefits in those with T1D, who have a very high cardiorenal risk, he said. 'ADJUST-T1D shows that T2D agents like semaglutide can definitely benefit T1Ds with no safety concerns.' For the time being, Shah pointed to this section of the ADA Standards of Care that was just added in the 2025 edition: A diagnosis of type 1 diabetes does not preclude also having features classically associated with type 2 diabetes (eg, insulin resistance, obesity, and other metabolic abnormalities), and until more precise subsets are used in clinical practice, it may be appropriate to categorize such an individual as having features of both type 1 and type 2 diabetes to facilitate access to appropriate treatment (eg, glucagon-like peptide 1 receptor agonist [GLP-1 RA] or sodium–glucose cotransporter 2 [SGLT2] inhibitor therapies for potential weight and other cardiometabolic benefits) and monitoring systems. 'We use that language from the Standards of Care in prior authorization,' Shah told Medscape Medical News . Independent Industry Consultant Charles Alexander, MD, told Medscape Medical News , 'This small study is very encouraging but unlikely to lead to [US Food and Drug Administration] approval for semaglutide in T1D. In contrast, two much larger currently recruiting global studies of tirzepatide in T1D NCT06914895 and NCT06962280 are more likely to lead, if successful, to FDA approval.' Shah received research support from, does consulting, speaking, and/or serves on advisory boards for Alexion, Novo Nordisk, Dexcom, Enable Bioscience, Zucara Therapeutics, Lilly, Breakthrough T1D, NIH, Insulet, Tandem Diabetes Care, Medtronic, Ascensia Diabetes Care, Embecta, Sanofi, Sequel Med Tech, Biomea Fusion, Lumosfit, and Genomelink. Argento has consulted or been on advisory boards for Eli Lilly Diabetes, Dexcom, DiabeLoop, ConvaTec, and Senseonics and served on the speakers' bureaus for Boehringer-Ingelheim, Dexcom, Eli Lilly Diabetes, MannKind, Novo Nordisk, Xeris, and Zealand Pharmaceuticals. Alexander had no disclosures.
